AEON Biopharma Initiates Enrollment in Phase 2 Trial of ABP-450 for the Preventive Treatment of Migraine -Clinical trial will enroll both episodic and chronic migraine patients- -Protocol utilizes streamlined treatment paradigm with fewer injections- -Topline data expected in mid-2022- NEWPORT BEACH,...

AEON Biopharma Announces FDA Acceptance of IND for ABP-450 as a Treatment for Cervical Dystonia; Secures $25 Million Investment -Critical milestone transitions AEON Biopharma to clinical-stage company- -Moving directly into Phase 2 clinical trial expected to begin in the first half of 2021- -Investment expected to provide...